# Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

> **NCT06056596** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 2 (actual)

## Conditions studied

- Retinal Detachment
- Rhegmatogenous Retinal Detachment

## Interventions

- **DRUG:** Lamivudine 300 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06056596
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-30
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Treatment approach changed, and insufficient population
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056596, "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06056596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*